"Hit" to lead optimization and chemoinformatic studies for a new series of Autotaxin inhibitors

Area of Science:

• Medicinal Chemistry
• Pharmacology
• Biochemistry

Background:

• The Autotaxin (ATX)/Lysophosphatidic acid (LPA) axis is implicated in chronic inflammation, fibroproliferative diseases, and cancer.
• Existing ATX inhibitors include substrate-, lipid-based, and small-molecule types, with ziritaxestat (GLPG-1690) reaching advanced clinical trials for idiopathic pulmonary fibrosis.

Purpose of the Study:

• To optimize the potency of a new series of Autotaxin inhibitors based on a novel 2-substituted-2,6-dihydro-4H-thieno[3,4-c]pyrazol-1-substituted amide scaffold.
• To investigate the mode of inhibition, cellular activity, solubility, and cytotoxicity of the synthesized ATX inhibitors.

Main Methods:

• Synthesis and chemical optimization of 2-substituted-2,6-dihydro-4H-thieno[3,4-c]pyrazol-1-substituted amide derivatives.
• In vitro evaluation of inhibitor potency, cellular activity, aqueous solubility, and cytotoxicity.
• Chemoinformatic analyses including molecular docking and molecular dynamics simulations.

Main Results:

• Identification of potent Autotaxin inhibitors within the 2-substituted-2,6-dihydro-4H-thieno[3,4-c]pyrazol-1-substituted amide series.
• Characterization of the pharmacological profile, including cellular activity and cytotoxicity, of lead compounds.
• Computational modeling provided insights into the binding mechanism of the synthesized inhibitors to Autotaxin.

Conclusions:

• The novel 2-substituted-2,6-dihydro-4H-thieno[3,4-c]pyrazol-1-substituted amide scaffold represents a promising starting point for developing new Autotaxin inhibitors.
• These optimized inhibitors warrant further investigation for therapeutic applications in ATX-related diseases, including fibrotic conditions and cancer.